

Supplemental material S2

Cardiometabolic monitoring trends for body composition (body weight, BMI); blood glucose; blood lipids by the associated cardiometabolic risks of antipsychotic.

Table S2-1: Trends in body compositions (body weight, BMI) monitoring performance by risks of weight gain associated with antipsychotic use.

BMI monitoring level	Weight gains associated risks with APs use					p-value†
	Limited/No data	Neutral/ low	Moderate	High	Total	
Never	13	6	35	12	66	0.2
Less frequent	15	29	77	33	154	
Standard	14	11	62	19	106	
More frequent	19	34	82	36	171	
Total	61	80	256	100	497	

†Results of chi-square (χ^2) & Fisher exact tests; *** p<.01, ** p<.05, * p<.1; NR: No records

Table S2-2: Trends in HbA1c monitoring performance by risks of hyperglycemia/diabetes associated with APs use

HbA1c monitoring level	Hyperglycaemia/diabetes risks associated with APs					p-value†
	Limited/No data	Minimal	Low	Moderate	High	
Never	10	88	64	247	83	0.3
Less frequent	NR	2	NR	1	2	
Total	10	90	64	248	85	

†Results of chi-square (χ^2) & Fisher exact tests; *** p<.01, ** p<.05, * p<.1; NR: No records

Table S2-3: Trends in lipid panel monitoring performance by risks dyslipidemia associated with APs use.

HDL monitoring level	Risks dyslipidaemia associated with APs use			
	Neutral/ Low	Moderate/High	Total	p-value†
Never	38	112	150	0.000***
Less frequent	69	125	194	
Standard	22	51	73	
More frequent	43	36	80	
Total	172	324	497	

Non-HDL monitoring level	Neutral/ Low	Moderate/High	Total	p-value†
Never	46	125	171	0.000***
Less frequent	67	125	192	
Standard	23	47	70	
More frequent	36	27	64	
Total	172	324	497	

†Results of chi-square (χ^2) & Fisher exact tests; *** $p < .01$, ** $p < .05$, * $p < .1$; NR: No records